Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer

Onkologie

Volumn 31, Issue 7, 2008, Pages 394-397

  Berretta, Massimiliano ^a   Lleshi, Arben ^a   Zanet, Ernesto ^a   Bearz, Alessandra ^a   Simonelli, Cecilia ^a   Fisichella, Rossella ^b   Nasti, Guglielmo ^c   Berretta, Salvatore ^b   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Bevacizumab; Chemotherapy; Colorectal cancer; HAART; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAMIVUDINE; OXALIPLATIN; PROTEINASE INHIBITOR; RITONAVIR PLUS FOSAMPRENAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANAMNESIS; ARTERY THROMBOSIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLON ADENOCARCINOMA; COLON RESECTION; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIVER METASTASIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OPPORTUNISTIC INFECTION; PERITONEUM METASTASIS; PROTEINURIA;

ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HIV INFECTIONS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 47049102052     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132360     Document Type: Article

References (17)

1. Chong G, Cunningham D: The role of cetuximab in the therapy of previously treated advanced colorectal cancer. Semin Oncol 2005;32(6 suppl 9):S55-8.
2. Diaz-Rubio E, Schmoll H-J: Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. Oncology 2005;69(suppl 3):1-3.
3. Hurwitz H, Fehrenbacher L, Novontry W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Boss R, Kabbinavir F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
4. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, Costagliola D, Salmon D, Chêne G, Morlat P: Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004;101:317-24.
5. Herida M, Mary-Krause M, Kaplan R, Cadranel J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM, Costagliola D: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447-53.
6. Cooley TP: Non-AIDS-defining cancer in HIV-infected people. Hematol Oncol Clin N AM 2003;17:889-99.
7. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD: Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006;24:1383-8.
8. Bedimo R, Chen RY, Accort NA, Raper JL, Linn C, Allison JJ, Dubay J, Saag MS, Hoesley CJ: Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004;39:1380-4.
9. Berretta M, Martellotta F, Spina M, Lleshi A, Di Gennaro G, Bearz A, Vaccher E, Sartor I, Rupolo M, Tirelli U: Clinical features and outcome of colorectal cancer in HIV-infected people: a GICAT experience. Gastrointestinal Cancers Symposium - Am Soc Clin Oncol GI Meeting, 2005, abstract 201.
10. Berretta M, Di Benedetto F, Simonelli C, Bearz A, Berretta S, Maugeri D, Tirelli U: Multidisciplinary approach in a HIV/HCV-positive patient with liver metastases by colorectal cancer in the HAART-era. Ann Oncol 2006;17:1333-4.
11. Berretta M, Simonelli C, Lleshi A, Lacchin T, Bearz A, Di Gennaro G, Vaccher E, Tirelli U: Oxaliplatin-based chemotherapy in association with highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients. Ann Oncol 2006;17:712-2.
12. Berretta M, Martellotta F, Simonelli C, Di Benedetto F, De Ruvo N, Drigo A, Bearz A, Spina M, Zanet E, Berretta S, Tirelli U: Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report. J Chemother 2007;19:343-6.
13. WHO: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48, Geneva, WHO, 1979.
14. Antoniou T, Tseng AL: Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005;44:111-45.
15. Corona G, Vaccher E, Cattarossi G, Sartor I, Toffoli G: Potential hazard of pharmacokinetic between lopinavir-ritonavir protease inhibitors and irinotecan. AIDS 2005;19:2043-4.
16. International Collaboration on HIV and Cancer: Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-30.
17. Biggar RJ: AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology 2001;15:439-48.